We discovered that PTPN11 was substantially expressed in cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), head and neck squamous cell carcinoma (HNSC), liver hepatocellular carcinoma (LIHC), and stomach adenocarcinoma (STAD) using the TIMER2 algorithm (Figure 1A). Here, PTPN11 is linked to cholangiocarcinoma.